MNKD - NASDAQ

MannKind Corporation

MNKD·NASDAQ

$3.36

-2.0%

HealthcareBiotechnology

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.04B

EPS0.0200

P/E Ratio168.00

Earnings Date08/05/2026

792.18M

Assets

101%

3Y+168.0%

5Y+629.0%

10Y+640.0%

843.20M

Total Liabilities

78%

3Y+54.0%

5Y+192.0%

10Y+190.0%

-51.02M

Total Equity

-35%

3Y-80.0%

5Y-72.0%

10Y-72.0%

MannKind Corporation Funding & Solvency Profile

MNKD · NASDAQ

Current Assets

Cash & Cash Equivalents74.88M

Net Receivables38.37M

Inventory35.31M

Other Current Assets46.55M

Total Current Assets292 M

Non-Current Assets

Property, Plant & Equipment82.42M

Goodwill & Intangible Assets72.67M

Long-Term Investments5.01M

Other Non-Current Assets340.50M

Total Non-Current Assets428 M

Total Assets

792.18M

Financial Health Analysis

Current Ratio

1.70x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Working Capital

121 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

37% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

MannKind Corporation Balance Sheet

MNKD • NASDAQ

MannKind Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	74.9M	46.3M	238.5M	69.8M	124.2M	67M	29.9M	71.2M	43.9M	22.9M	59.1M	120.8M	70.8M	61.8M	2.7M	66.1M	30M	27.6M	368.3M	319.6M
Short-Term Investments	96.5M	150.9M	56.6M	101.1M	79.9M	0.0	20M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	515K	4.4M	2.5M	18.8M	0.0	116.9M
Cash & Short-Term Investments	171.3M	197.3M	295.1M	170.8M	204.1M	67M	49.9M	71.2M	43.9M	22.9M	59.1M	120.8M	70.8M	61.8M	3.2M	70.4M	32.5M	46.5M	368.3M	436.5M
Net Receivables	38.4M	11.8M	14.9M	16.8M	4.7M	4.2M	3.5M	4M	2.8M	30.9M	23K	50.4M	0.0	450K	0.0	674K	1.5M	1.5M	831K	2.4M
Accounts Receivables	38.4M	11.8M	14.9M	16.8M	4.7M	4.2M	3.5M	4M	2.8M	302K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.6M	23K	50.4M	0.0	450K	0.0	674K	1.5M	1.5M	831K	2.4M
Inventory	35.3M	27.9M	28.5M	21.8M	7.2M	5M	4.2M	3.6M	2.7M	2.3M	13.5M	9.7M	-298K	-450K	-473K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	3.5M	3.1M	2.9M	2.6M	2.6M	4.4M	4M	20.2M	5.5M	4.5M	3.1M	2.8M	3.7M	6M	9.6M	10.7M
Other Current Assets	46.6M	31.4M	34.8M	25.5M	0.0	158K	316K	527K	5.2M	17M	13.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	291.6M	268.3M	373.4M	234.9M	219.5M	79.5M	60.8M	81.9M	57.2M	77.5M	76.7M	201.2M	76.3M	66.8M	5.8M	74M	37.7M	54M	378.7M	449.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	82.4M	85.4M	84.2M	45.1M	36.6M	25.9M	26.8M	25.6M	26.9M	28.9M	48.7M	192.1M	176.6M	184M	193M	202.4M	208.2M	226.4M	162.7M	88.3M
Goodwill	67.6M	1.9M	1.9M	2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	5.1M	5.3M	1.1M	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	72.7M	7.2M	3M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	5M	5.5M	7.2M	2M	56.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	340.5M	27.5M	7.4M	9.7M	8.4M	3.3M	6.2M	249K	437K	648K	1M	1.2M	5.8M	543K	703K	946K	1.5M	2M	2M	1.9M
Total Non-Current Assets	500.6M	125.5M	101.8M	60.4M	101.7M	29.1M	33M	25.9M	27.4M	29.6M	49.8M	193.3M	182.4M	184.5M	193.7M	203.3M	209.7M	228.5M	164.7M	90.2M
Total Assets	792.2M	393.8M	475.2M	295.3M	321.2M	108.6M	93.7M	107.7M	84.6M	107.1M	126.4M	394.4M	258.6M	251.3M	199.6M	277.3M	247.4M	282.5M	543.4M	539.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9M	6.8M	11.1M	11.1M	7M	5.6M	4.8M	5.4M	7M	3.3M	15.6M	7.4M	3.9M	4.6M	4.6M	3.3M	6.5M	15.6M	35.5M	10.7M
Accounts Payable	9M	6.8M	9.6M	11.1M	7M	5.6M	4.8M	5.4M	7M	3.3M	15.6M	7.4M	3.9M	4.6M	4.6M	3.3M	6.5M	15.6M	35.5M	10.7M
Other Payables	0.0	49K	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	32.2M	32.9M	28.5M	24.1M	17.3M	13.2M	11.8M	11.9M	7.6M	4.2M	17.3M	15.6M	10.1M	9M	14.8M	22.3M	37.8M	32.1M	7.3M
Short Term Debt	49.2M	0.0	20M	9.6M	7M	4.1M	5M	11.3M	52.7M	71.3M	74.6M	172.4M	102.3M	114.4M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	49K	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	15.3M	12.4M	9.1M	1.7M	827K	33.3M	32.5M	50.9M	3M	3.4M	17.5M	216.1M	15.9M	24.5M	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	97.4M	30.4M	31M	16.4M	9.5M	13.5M	10.1M	46.8M	13M	6.4M	174M	206.3M	6M	15.7M	11.7M	0.0	0.0	0.0	0.0	27M
Total Current Liabilities	171M	81.8M	104.1M	67.3M	48.3M	73.7M	65.6M	75.2M	87.6M	92.1M	268.3M	403.4M	127.8M	144.8M	25.4M	18.1M	28.9M	53.5M	67.6M	45M
NON-CURRENT LIABILITIES
Long Term Debt	320.4M	36.1M	248.7M	273.5M	281.2M	118.2M	113.9M	91.2M	104.1M	77.2M	139.5M	49.5M	148M	217.2M	487.8M	444.7M	277.8M	142.3M	111.8M	111.3M
Deferred Revenue (Non-Current)	40M	51.2M	69.8M	37.7M	24.5M	1.7M	8.3M	10.7M	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.7M	-500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	208.1M	292M	294.8M	162M	175.4M	94.3M	93.9M	105.7M	107.6M	121.4M	68.9M	15.3M	13.6M	0.0	0.0	0.0	0.0	0.0	24K	24K
Total Non-Current Liabilities	672.2M	390.8M	617.2M	478.5M	482.2M	215.3M	218.6M	207.5M	211.7M	198.6M	208.4M	64.9M	161.6M	217.2M	487.8M	444.7M	277.8M	142.3M	111.8M	111.3M
Capital Lease Obligations	103.8M	11.6M	3.9M	5.3M	1M	1.2M	2.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	843.2M	472.7M	721.4M	545.8M	530.5M	289M	284.3M	282.8M	299.3M	290.7M	476.7M	468.2M	289.4M	362M	513.2M	462.8M	306.6M	195.7M	179.3M	156.3M
SHAREHOLDERS' EQUITY
Common Stock	3.1M	3M	2.7M	2.6M	2.5M	2.4M	2.1M	1.9M	1.2M	4.8M	4.3M	4.1M	3.7M	2.9M	1.3M	1.3M	1.1M	1M	1M	734K
Additional Paid-In Capital	3.1B	3.1B	3B	3B	2.9B	2.9B	2.8B	2.8B	2.6B	2.5B	2.5B	2.4B	2.3B	2B	1.6B	1.6B	1.5B	1.5B	1.4B	1.2B
Retained Earnings	-3.2B	-3.2B	-3.2B	-3.2B	-3.1B	-3B	-3B	-2.9B	-2.9B	-2.7B	-2.9B	-2.5B	-2.3B	-2.1B	-1.9B	-1.8B	-1.6B	-1.4B	-1.1B	-787.8M
Accumulated Other Comprehensive Income/Loss	115K	1.1M	0.0	0.0	0.0	0.0	-19K	-19K	-18K	-24K	-20K	-14K	-4K	-6K	44K	74K	-281K	295K	-40.7M	-33.1M
Total Stockholders' Equity	-51M	-78.8M	-246.2M	-250.5M	-209.3M	-180.4M	-190.5M	-175.1M	-214.7M	-183.6M	-350.3M	-73.8M	-30.7M	-110.7M	-313.7M	-185.5M	-59.2M	86.7M	364.1M	383.5M
Total Equity	-51M	-78.8M	-246.2M	-250.5M	-209.3M	-180.4M	-190.5M	-175.1M	-214.7M	-183.6M	-350.3M	-73.8M	-30.7M	-110.7M	-313.7M	-185.5M	-59.2M	86.7M	364.1M	383.5M
SUMMARY
Total Liabilities & Equity	792.2M	393.8M	475.2M	295.3M	321.2M	108.6M	93.7M	107.7M	84.6M	107.1M	126.4M	394.4M	258.6M	251.3M	199.6M	277.3M	247.4M	282.5M	543.4M	539.7M
Total Investments	101.5M	156.4M	63.8M	103M	136.6M	0.0	20M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	515K	4.4M	2.5M	18.8M	0.0	116.9M
Total Debt	473.4M	47.7M	272.6M	288.4M	289.2M	123.4M	121.4M	102.5M	156.8M	148.5M	139.5M	49.5M	148M	217.2M	487.8M	444.7M	277.8M	142.3M	111.8M	111.3M
Net Debt	398.5M	1.4M	34.1M	218.6M	165M	56.4M	91.5M	31.3M	112.9M	125.6M	80.4M	-71.3M	77.2M	155.4M	485.2M	378.6M	247.7M	114.6M	-256.5M	-208.3M
Shares Outstanding	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093	307,007,093

SEC Filings

MNKD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 28, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	December 15, 2025	October 07, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 08, 2025	2025	View Filing

Showing 1 to 10 of 417 filings

Related Guides

Blog Categories

Continue your MNKD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.